Close Menu

NEW YORK – Ambry Genetics announced on Monday that its +RNAinsight combined DNA-RNA genetic test for hereditary cancer syndromes has received approval from the New York State Clinical Laboratory Evaluation Program (CLEP).

The +RNAinsight test, which was launched in October, enables clinicians to conduct both DNA and RNA genetic testing at the same time, with the aim of returning more specific results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.